Bolt Biotherapeutics (NASDAQ:BOLT) Major Shareholder Coastlands Capital Lp Acquires 33,094 Shares of Company Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) major shareholder Coastlands Capital Lp acquired 33,094 shares of the firm’s stock in a transaction on Monday, November 16th. The stock was purchased at an average price of $5.89 per share, with a total value of $194,923.66. Following the acquisition, the insider owned 495,510 shares of the company’s stock, valued at $2,918,553.90. This represents a 7.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Coastlands Capital Lp also recently made the following trade(s):

  • On Tuesday, November 17th, Coastlands Capital Lp acquired 20,000 shares of Bolt Biotherapeutics stock. The shares were purchased at an average cost of $5.75 per share, with a total value of $115,000.00.
  • On Monday, November 9th, Coastlands Capital Lp acquired 50,000 shares of Bolt Biotherapeutics stock. The shares were purchased at an average cost of $6.38 per share, with a total value of $319,000.00.

Bolt Biotherapeutics Stock Performance

Shares of BOLT stock opened at $5.65 on Wednesday. Bolt Biotherapeutics, Inc. has a 12 month low of $3.10 and a 12 month high of $7.78. The stock has a market cap of $14.75 million, a PE ratio of -0.38 and a beta of 0.85. The company has a current ratio of 2.05, a quick ratio of 2.61 and a debt-to-equity ratio of 2.06. The company’s fifty day moving average price is $4.70 and its 200-day moving average price is $4.51.

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($2.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.68) by $1.43. The firm had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.45 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 154.11%. On average, equities analysts expect that Bolt Biotherapeutics, Inc. will post -11.10 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Bolt Biotherapeutics stock. Renaissance Technologies LLC raised its stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) by 40.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,225 shares of the company’s stock after buying an additional 22,200 shares during the quarter. Renaissance Technologies LLC owned about 4.02% of Bolt Biotherapeutics worth $312,000 at the end of the most recent quarter. 86.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Bolt Biotherapeutics currently has an average rating of “Hold” and a consensus target price of $14.50.

Get Our Latest Report on Bolt Biotherapeutics

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer. The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate.

Featured Stories

Insider Buying and Selling by Quarter for Bolt Biotherapeutics (NASDAQ:BOLT)

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.